GET DAILY SIGNALSQiagen Shows Operational Strength in Q3 as EQT Deal Progresses (QGEN)
Key Takeaways
- Net sales rose 3% year over year to $548 million in the third quarter of 2026, matching the company's preliminary figures released in late October.
- Adjusted diluted earnings per share (EPS) of $0.65 came in ahead of the company's own outlook of at least $0.62 at constant exchange rates (CER).
- Adjusted operating income margin expanded 0.8 percentage points to 30.4%, supported by higher-margin consumables and efficiency gains.
- Reported (GAAP) diluted EPS declined to $0.51 from $0.60 a year earlier, reflecting acquisition-related and other items.
- Qiagen has suspended its full-year 2026 guidance pending the completion of its proposed acquisition by EQT Private Equity.
Earnings Context and Why It Matters
Qiagen N.V. is a global provider of molecular diagnostics and sample-to-insight technologies used to isolate and analyze DNA and RNA. This third-quarter 2026 earnings report carries unusual weight because it lands against a major corporate backdrop: on October 22, 2026, QGEN announced a definitive agreement to be acquired by EQT Private Equity in an all-cash deal valued at roughly €10.8 billion. As a result, investors are weighing solid operational momentum against the mechanics of the pending transaction. The company suspended its annual outlook and skipped its usual conference call, making these reported figures one of the clearest remaining snapshots of underlying business performance.
Reported Results
QGEN reported third-quarter 2026 net sales of $548 million, an increase of 3% over the prior-year period and in line with its preliminary announcement. Adjusted diluted EPS was $0.65, up 7% from $0.61 a year earlier and above the company's outlook of at least $0.62 at constant exchange rates (CER, which strips out currency fluctuations). Reported diluted EPS, which includes acquisition-related items, fell to $0.51 from $0.60.
Adjusted operating income rose 6% to $167 million, driving the adjusted operating income margin to 30.4%, up from 29.6% in the third quarter of 2025. Management attributed the improvement to sales growth, a growing contribution from higher-margin consumables, and efficiency gains that helped fund investments in Parse Biosciences, acquired in late 2025. Operating cash flow reached $447 million for the first nine months of 2026. The adjusted EPS figure exceeded consensus estimates of roughly $0.62 to $0.63, while revenue came in above the approximately $538 million analysts had expected. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
QGEN stock has been trading largely in step with the terms of the EQT transaction rather than its quarterly fundamentals. The agreement values the company at €46.50 per share, representing a premium of about 40% to Qiagen's closing price on July 8, 2026. With shares hovering near $50 in U.S. trading, the stock sits just below the implied offer, leaving limited room tied to operating results. Sentiment has shifted decisively toward deal mechanics: several analysts downgraded the stock to a neutral or hold stance following the announcement, and the suspension of guidance has removed a key valuation anchor. As a result, the market's response to these earnings is expected to be muted relative to a typical reporting period.
Forward Outlook and Key Factors to Monitor
Looking ahead, the dominant factor for Qiagen shareholders is the progress of the EQT acquisition. The offer process has not yet formally begun, and the tender offer document must first receive approval from Germany's BaFin regulator before it can be published. Investors will be watching the timing of that publication, the terms of any offer, and the completion of regulatory approvals across relevant jurisdictions.
On the operational side, the third-quarter results showed a constructive mix, with consumables accounting for the large majority of sales and growth drivers contributing about $415 million in revenue, up 7% year over year. That strength was partially offset by declines in the rest of the portfolio, which is worth monitoring for signs of stabilization.
Because Qiagen has suspended its full-year 2026 guidance, investors no longer have the company's forward targets as a reference point. Without a conference call, visibility into management's near-term expectations is reduced. The key question for shareholders is no longer solely about margins or revenue growth, but whether the transaction closes on the announced terms and timeline.
Using AI Tools in Portfolio Analysis
I often turn to Tickeron’s AI Screener when evaluating names like QGEN alongside peers in diagnostics. It lets me apply custom filters for technical patterns, fundamentals, and performance metrics, helping surface comparable setups quickly. In this case, it confirmed the relative stability in the sector and highlighted a few other life-sciences names worth tracking during the deal period. The tool has become a regular part of my workflow for staying objective when news flow dominates price action.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QGEN in upward trend: price rose above 50-day moving average on October 02, 2026
QGEN moved above its 50-day moving average on October 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on QGEN as a result. In 46 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for QGEN just turned positive on October 05, 2026. Looking at past instances where QGEN's MACD turned positive, the stock continued to rise in 22 of 39 cases over the following month. The odds of a continued upward trend are 56%.
Following a +0.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where QGEN advanced for three days, in 139 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 52%.
The Aroon Indicator entered an Uptrend today. In 105 of 191 cases where QGEN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 13 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
QGEN broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.098) is normal, around the industry mean (65.986). P/E Ratio (25.343) is within average values for comparable stocks, (3.066). Projected Growth (PEG Ratio) (1.201) is also within normal values, averaging (3.473). QGEN's Dividend Yield (0.028) is considerably higher than the industry average of (0.002). P/S Ratio (4.255) is also within normal values, averaging (9.775).
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. QGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 51 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 91 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of sample and assay technology products for preanalytical sample preparations
Industry MedicalSpecialties